|Source plant(s)||Cannabis sativa, Cannabis indica, Cannabis ruderalis|
|Part(s) of plant||Flower and fruit|
|Geographic origin||Central Asia and Indian subcontinent|
|Active ingredients||Tetrahydrocannabinol, cannabidiol, cannabinol, tetrahydrocannabivarin|
|Main producers||Afghanistan, Canada, China, Colombia, India, Jamaica, Lebanon, Mexico, Morocco, Netherlands, Pakistan, Paraguay, Spain, Thailand, Turkey, United Kingdom, United States|
Cannabis, also known as marijuana among other names,[a] is a psychoactive drug from the Cannabis plant used primarily for medical and recreational purposes. Tetrahydrocannabinol (THC) is the main psychoactive component of cannabis, which is one of the 483 known compounds in the plant, including at least 65 other cannabinoids, including cannabidiol (CBD). Cannabis can be used by smoking, vaporizing, within food, or as an extract.
Cannabis has various mental and physical effects, which include euphoria, altered states of mind and sense of time, difficulty concentrating, impaired short-term memory and body movement, relaxation, and an increase in appetite. Onset of effects is felt within minutes when smoked, and about 30 to 60 minutes when cooked and eaten. The effects last for two to six hours, depending on the amount used. At high doses, mental effects can include anxiety, delusions (including ideas of reference), hallucinations, panic, paranoia, and psychosis. There is a strong relation between cannabis use and the risk of psychosis, though the direction of causality is debated. Physical effects include increased heart rate, difficulty breathing, nausea, and behavioral problems in children whose mothers used cannabis during pregnancy; short-term side effects may also include dry mouth and red eyes. Long-term adverse effects may include addiction, decreased mental ability in those who started regular use as adolescents, chronic coughing, and susceptibility to respiratory infections.
Cannabis is mostly used recreationally or as a medicinal drug, although it may also be used for spiritual purposes. In 2013, between 128 and 232 million people used cannabis (2.7% to 4.9% of the global population between the ages of 15 and 65). It is the most commonly used illegal drug in the world, though it is legal in some jurisdictions, with the highest use among adults (as of 2018[update]) in Zambia, the United States, Canada, and Nigeria.
While cannabis plants have been grown since at least the 3rd millennium BCE, evidence suggests that it was being smoked for psychoactive effects at least 2,500 years ago in the Pamir Mountains; the earliest evidence found at a cemetery in what is today western China close to the tripoint with Tajikistan and Afghanistan. Since the early 20th century, cannabis has been subject to legal restrictions. The possession, use, and cultivation of cannabis is illegal in most countries of the world. In 2013, Uruguay became the first country to legalize recreational use of cannabis. Other countries to do so are Canada, Georgia, and South Africa, plus 17 states, 2 territories, and the District of Columbia in the United States (though the drug remains federally illegal). Medical use of cannabis, requiring the approval of a physician, has been legalized in a greater number of countries.
Medical cannabis, or medical marijuana, can refer to the use of cannabis and its cannabinoids to treat disease or improve symptoms; however, there is no single agreed-upon definition. The rigorous scientific study of cannabis as a medicine has been hampered by production restrictions and by the fact that it is classified as an illegal drug by many governments. There is limited evidence suggesting cannabis can be used to reduce nausea and vomiting during chemotherapy, to improve appetite in people with HIV/AIDS, or to treat chronic pain and muscle spasms. Its use for other medical applications is insufficient for drawing conclusions about safety or efficacy.
Short-term use increases the risk of both minor and major adverse effects. Common side effects include dizziness, feeling tired and vomiting. The long-term effects of cannabis are not clear. There are concerns surrounding memory and cognition problems, risk of addiction, risk of schizophrenia in young people, and the risk of children taking it by accident.
Cannabis has psychoactive and physiological effects when consumed. The immediate desired effects from consuming cannabis include relaxation and euphoria (the "high" or "stoned" feeling), a general alteration of conscious perception, increased awareness of sensation, increased libido and distortions in the perception of time and space. At higher doses, effects can include altered body image, auditory and/or visual illusions, pseudohallucinations and ataxia from selective impairment of polysynaptic reflexes. In some cases, cannabis can lead to dissociative states such as depersonalization and derealization.
Some immediate undesired side effects include a decrease in short-term memory, dry mouth, impaired motor skills and reddening of the eyes. Aside from a subjective change in perception and mood, the most common short-term physical and neurological effects include increased heart rate, increased appetite and consumption of food, lowered blood pressure, impairment of short-term and working memory, psychomotor coordination, and concentration. Some users may experience an episode of acute psychosis, which usually abates after six hours, but in rare instances, heavy users may find the symptoms continuing for many days.
A reduced quality of life is associated with heavy cannabis use, although the relationship is inconsistent and weaker than for tobacco and other substances. The direction of cause and effect, however, is unclear.
Cannabis has held sacred status in several religions and has served as an entheogen – a chemical substance used in religious, shamanic, or spiritual contexts – in the Indian subcontinent since the Vedic period dating back to approximately 1500 BCE, but perhaps as far back as 2000 BCE. There are several references in Greek mythology to a powerful drug that eliminated anguish and sorrow. Herodotus wrote about early ceremonial practices by the Scythians, thought to have occurred from the 5th to 2nd century BCE. In modern culture, the spiritual use of cannabis has been spread by the disciples of the Rastafari movement who use cannabis as a sacrament and as an aid to meditation. The earliest known reports regarding the sacred status of cannabis in the Indian subcontinent come from the Atharva Veda, estimated to have been composed sometime around 1400 BCE.
- Smoking, which typically involves burning and inhaling vaporized cannabinoids ("smoke") from small pipes, bongs (portable versions of hookahs with a water chamber), paper-wrapped joints or tobacco-leaf-wrapped blunts, and other items.
- Vaporizer, which heats any form of cannabis to 165–190 °C (329–374 °F), causing the active ingredients to evaporate into vapor without burning the plant material (the boiling point of THC is 157 °C (315 °F) at atmospheric pressure).
- Cannabis tea, which contains relatively small concentrations of THC because THC is an oil (lipophilic) and is only slightly water-soluble (with a solubility of 2.8 mg per liter). Cannabis tea is made by first adding a saturated fat to hot water (e.g. cream or any milk except skim) with a small amount of cannabis.
- Edibles, where cannabis is added as an ingredient to one of a variety of foods, including butter and baked goods. In India it is commonly made into a beverage, bhang.
- Capsules, typically containing cannabis oil, and other dietary supplement products, for which some 220 were approved in Canada in 2018.
Acute effects may include anxiety and panic, impaired attention and memory, an increased risk of psychotic symptoms,[b] the inability to think clearly, and an increased risk of accidents. Cannabis impairs a person's driving ability, and THC was the illicit drug most frequently found in the blood of drivers who have been involved in vehicle crashes. Those with THC in their system are from three to seven times more likely to be the cause of the accident than those who had not used either cannabis or alcohol, although its role is not necessarily causal because THC stays in the bloodstream for days to weeks after intoxication.[c]
According to the United States Department of Health and Human Services, there were 455,000 emergency room visits associated with cannabis use in 2011. These statistics include visits in which the patient was treated for a condition induced by or related to recent cannabis use. The drug use must be "implicated" in the emergency department visit, but does not need to be the direct cause of the visit. Most of the illicit drug emergency room visits involved multiple drugs. In 129,000 cases, cannabis was the only implicated drug.
The short term effects of cannabis can be altered if it has been laced with opioid drugs such as heroin or fentanyl. The added drugs are meant to enhance the psychoactive properties, add to its weight, and increase profitability, despite the increased danger of overdose.[d]
Heavy, long-term exposure to marijuana may have biologically based physical, mental, behavioral and social health consequences and may be "associated with diseases of the liver (particularly with co-existing hepatitis C), lungs, heart, and vasculature". Mothers who used marijuana during pregnancy have children with elevated levels of depression, hyperactivity, impulsivity and inattention. It is recommended that cannabis use be stopped before and during pregnancy as it can result in negative outcomes for both the mother and baby. However, maternal use of marijuana during pregnancy does not appear to be associated with low birth weight or early delivery after controlling for tobacco use and other confounding factors. A 2014 review found that while cannabis use may be less harmful than alcohol use, the recommendation to substitute it for problematic drinking was premature without further study. Various surveys conducted between 2015 and 2019 found that many users of cannabis substitute it for prescription drugs (including opioids), alcohol, and tobacco; most of those who used it in place of alcohol or tobacco either reduced or stopped their intake of the latter substances.
A limited number of studies have examined the effects of cannabis smoking on the respiratory system. Chronic heavy marijuana smoking is associated with coughing, production of sputum, wheezing, and other symptoms of chronic bronchitis. The available evidence does not support a causal relationship between cannabis use and chronic obstructive pulmonary disease. Short-term use of cannabis is associated with bronchodilation. Other side effects of cannabis use include cannabinoid hyperemesis syndrome (CHS).
Cannabis smoke contains thousands of organic and inorganic chemical compounds. This tar is chemically similar to that found in tobacco smoke, and over fifty known carcinogens have been identified in cannabis smoke, including; nitrosamines, reactive aldehydes, and polycylic hydrocarbons, including benz[a]pyrene. Cannabis smoke is also inhaled more deeply than tobacco smoke. As of 2015[update], there is no consensus regarding whether cannabis smoking is associated with an increased risk of cancer. Light and moderate use of cannabis is not believed to increase risk of lung or upper airway cancer. Evidence for causing these cancers is mixed concerning heavy, long-term use. In general there are far lower risks of pulmonary complications for regular cannabis smokers when compared with those of tobacco. A 2015 review found an association between cannabis use and the development of testicular germ cell tumors (TGCTs), particularly non-seminoma TGCTs. Another 2015 meta-analysis found no association between lifetime cannabis use and risk of head or neck cancer. Combustion products are not present when using a vaporizer, consuming THC in pill form, or consuming cannabis foods.
There is concern that cannabis may contribute to cardiovascular disease, but as of 2018, evidence of this relationship was unclear. Research in these events is complicated because cannabis is often used in conjunction with tobacco, and drugs such as alcohol and cocaine. Smoking cannabis has also been shown to increase the risk of myocardial infarction by 4.8 times for the 60 minutes after consumption.
Although global abnormalities in white matter and grey matter are not associated with heavy cannabis use, reduced hippocampal volume is consistently found. Amygdala abnormalities are sometimes reported, although findings are inconsistent.
Cannabis use is associated with increased recruitment of task-related areas, such as the dorsolateral prefrontal cortex, which is thought to reflect compensatory activity due to reduced processing efficiency. Cannabis use is also associated with downregulation of CB1 receptors. The magnitude of down regulation is associated with cumulative cannabis exposure, and is reversed after one month of abstinence. There is limited evidence that chronic cannabis use can reduce levels of glutamate metabolites in the human brain.
A 2015 meta analysis found that, although a longer period of abstinence was associated with smaller magnitudes of impairment, both retrospective and prospective memory were impaired in cannabis users. The authors concluded that some, but not all, of the deficits associated with cannabis use were reversible. A 2012 meta analysis found that deficits in most domains of cognition persisted beyond the acute period of intoxication, but was not evident in studies where subjects were abstinent for more than 25 days. Few high quality studies have been performed on the long-term effects of cannabis on cognition, and the results were generally inconsistent. Furthermore, effect sizes of significant findings were generally small. One review concluded that, although most cognitive faculties were unimpaired by cannabis use, residual deficits occurred in executive functions. Impairments in executive functioning are most consistently found in older populations, which may reflect heavier cannabis exposure, or developmental effects associated with adolescent cannabis use. One review found three prospective cohort studies that examined the relationship between self reported cannabis use and intelligence quotient (IQ). The study following the largest number of heavy cannabis users reported that IQ declined between ages 7–13 and age 38. Poorer school performance and increased incidence of leaving school early were both associated with cannabis use, although a causal relationship was not established. Cannabis users demonstrated increased activity in task-related brain regions, consistent with reduced processing efficiency.
At an epidemiological level, a dose–response relationship exists between cannabis use and increased risk of psychosis and earlier onset of psychosis. Although the epidemiological association is robust, evidence to prove a causal relationship is lacking. But a biological causal pathway is plausible, especially if there is a genetic predisposition to mental illness, in which case cannabis may be a trigger.[better source needed]
It is not clear whether cannabis use affects the rate of suicide. Cannabis may also increase the risk of depression, but insufficient research has been performed to draw a conclusion. Cannabis use is associated with increased risk of anxiety disorders, although causality has not been established.
A February 2019 review found that cannabis use during adolescence was associated with an increased risk of developing depression and suicidal behavior later in life, while finding no effect on anxiety.
About 9% of those who experiment with marijuana eventually become dependent according to DSM-IV (1994) criteria. A 2013 review estimates daily use is associated with a 10–20% rate of dependence. The highest risk of cannabis dependence is found in those with a history of poor academic achievement, deviant behavior in childhood and adolescence, rebelliousness, poor parental relationships, or a parental history of drug and alcohol problems. Of daily users, about 50% experience withdrawal upon cessation of use (i.e. are dependent), characterized by sleep problems, irritability, dysphoria, and craving. Cannabis withdrawal is less severe than withdrawal from alcohol.
According to DSM-V criteria, 9% of those who are exposed to cannabis develop cannabis use disorder, compared to 20% for cocaine, 23% for alcohol and 68% for nicotine. Cannabis use disorder in the DSM-V involves a combination of DSM-IV criteria for cannabis abuse and dependence, plus the addition of craving, without the criterion related to legal troubles.
THC, the principal psychoactive constituent of the cannabis plant, has low toxicity. The dose of THC needed to kill 50% of tested rodents is extremely high. Cannabis has not been reported to cause fatal overdose in humans, and it would be extremely difficult to consume enough natural cannabis to cause an overdose using traditional methods like smoking it. This renders the risk of accidental overdose a practical impossibility, unless purified THC is involved.
Mechanism of action
The high lipid-solubility of cannabinoids results in their persisting in the body for long periods of time. Even after a single administration of THC, detectable levels of THC can be found in the body for weeks or longer (depending on the amount administered and the sensitivity of the assessment method). Investigators have suggested that this is an important factor in marijuana's effects, perhaps because cannabinoids may accumulate in the body, particularly in the lipid membranes of neurons.
Researchers confirmed that THC exerts its most prominent effects via its actions on two types of cannabinoid receptors, the CB1 receptor and the CB2 receptor, both of which are G protein-coupled receptors. The CB1 receptor is found primarily in the brain as well as in some peripheral tissues, and the CB2 receptor is found primarily in peripheral tissues, but is also expressed in neuroglial cells. THC appears to alter mood and cognition through its agonist actions on the CB1 receptors, which inhibit a secondary messenger system (adenylate cyclase) in a dose-dependent manner.
Via CB1 receptor activation, THC indirectly increases dopamine release and produces psychotropic effects. CBD also acts as an allosteric modulator of the μ- and δ-opioid receptors. THC also potentiates the effects of the glycine receptors. It is unknown if or how these actions contribute to the effects of cannabis.
Detection in body fluids
THC and its major (inactive) metabolite, THC-COOH, can be measured in blood, urine, hair, oral fluid or sweat using chromatographic techniques as part of a drug use testing program or a forensic investigation of a traffic or other criminal offense. The concentrations obtained from such analyses can often be helpful in distinguishing active use from passive exposure, elapsed time since use, and extent or duration of use. These tests cannot, however, distinguish authorized cannabis smoking for medical purposes from unauthorized recreational smoking. Commercial cannabinoid immunoassays, often employed as the initial screening method when testing physiological specimens for marijuana presence, have different degrees of cross-reactivity with THC and its metabolites. Urine contains predominantly THC-COOH, while hair, oral fluid and sweat contain primarily THC. Blood may contain both substances, with the relative amounts dependent on the recency and extent of usage.
The Duquenois–Levine test is commonly used as a screening test in the field, but it cannot definitively confirm the presence of cannabis, as a large range of substances have been shown to give false positives. Researchers at John Jay College of Criminal Justice reported that dietary zinc supplements can mask the presence of THC and other drugs in urine. However, a 2013 study conducted by researchers at the University of Utah School of Medicine refute the possibility of self-administered zinc producing false-negative urine drug tests.
Varieties and strains
CBD is a 5-HT1A receptor agonist, which is under laboratory research to determine if it has an anxiolytic effect. It is often claimed that sativa strains provide a more stimulating psychoactive high while indica strains are more sedating with a body high. However, this is disputed by researchers.
According to the United Nations Office on Drugs and Crime (UNODC), "the amount of THC present in a cannabis sample is generally used as a measure of cannabis potency." The three main forms of cannabis products are the flower/fruit, resin (hashish), and oil (hash oil). The UNODC states that cannabis often contains 5% THC content, resin "can contain up to 20% THC content", and that "Cannabis oil may contain more than 60% THC content."
A 2012 review found that the THC content in marijuana had increased worldwide from 1970 to 2009. It is unclear, however, whether the increase in THC content has caused people to consume more THC or if users adjust based on the potency of the cannabis. It is likely that the higher THC content allows people to ingest less tar. At the same time, CBD levels in seized samples have lowered, in part because of the desire to produce higher THC levels and because more illegal growers cultivate indoors using artificial lights. This helps avoid detection but reduces the CBD production of the plant.
Australia's National Cannabis Prevention and Information Centre (NCPIC) states that the buds (infructescences) of the female cannabis plant contain the highest concentration of THC, followed by the leaves. The stalks and seeds have "much lower THC levels". The UN states that the leaves can contain ten times less THC than the buds, and the stalks one hundred times less THC.
After revisions to cannabis scheduling in the UK, the government moved cannabis back from a class C to a class B drug. A purported reason was the appearance of high potency cannabis. They believe skunk accounts for between 70 and 80% of samples seized by police (despite the fact that skunk can sometimes be incorrectly mistaken for all types of herbal cannabis). Extracts such as hashish and hash oil typically contain more THC than high potency cannabis infructescences.
A gram of kief
Marijuana or marihuana (herbal cannabis) consists of the dried flowers and fruits and subtending leaves and stems of the female Cannabis plant. This is the most widely consumed form, containing 3% to 20% THC, with reports of up to 33% THC. This is the stock material from which all other preparations are derived. Although herbal cannabis and industrial hemp derive from the same species and contain the psychoactive component (THC), they are distinct strains with unique biochemical compositions and uses. Hemp has lower concentrations of THC and higher concentrations of CBD, which gives lesser psychoactive effects.
Kief is a powder, rich in trichomes, which can be sifted from the leaves, flowers and fruits of cannabis plants and either consumed in powder form or compressed to produce cakes of hashish. The word "kif" derives from colloquial Arabic كيف kēf/kīf, meaning pleasure.
Hashish (also spelled hasheesh, hashisha, or simply hash) is a concentrated resin cake or ball produced from pressed kief, the detached trichomes and fine material that falls off cannabis fruits, flowers and leaves. or from scraping the resin from the surface of the plants and rolling it into balls. It varies in color from black to golden brown depending upon purity and variety of cultivar it was obtained from. It can be consumed orally or smoked, and is also vaporized, or 'vaped'. The term "rosin hash" refers to a high quality solventless product obtained through heat and pressure.
Cannabinoids can be extracted from cannabis plant matter using high-proof spirits (often grain alcohol) to create a tincture, often referred to as "green dragon". Nabiximols is a branded product name from a tincture manufacturing pharmaceutical company.
Hash oil is a resinous matrix of cannabinoids obtained from the Cannabis plant by solvent extraction, formed into a hardened or viscous mass. Hash oil can be the most potent of the main cannabis products because of its high level of psychoactive compound per its volume, which can vary depending on the plant's mix of essential oils and psychoactive compounds. Butane and supercritical carbon dioxide hash oil have become popular in recent years.
There are many varieties of cannabis infusions owing to the variety of non-volatile solvents used. The plant material is mixed with the solvent and then pressed and filtered to express the oils of the plant into the solvent. Examples of solvents used in this process are cocoa butter, dairy butter, cooking oil, glycerine, and skin moisturizers. Depending on the solvent, these may be used in cannabis foods or applied topically.
Medical marijuana refers to the use of the Cannabis plant as a physician-recommended herbal therapy as well as synthetic THC and cannabinoids. So far, the medical use of cannabis is legal only in a limited number of territories, including Canada, Belgium, Australia, the Netherlands, New Zealand, Spain, and many U.S. states. This usage generally requires a prescription, and distribution is usually done within a framework defined by local laws. There is evidence supporting the use of cannabis or its derivatives in the treatment of chemotherapy-induced nausea and vomiting, neuropathic pain, and multiple sclerosis. Lower levels of evidence support its use for AIDS wasting syndrome, epilepsy, rheumatoid arthritis, and glaucoma.
Cannabis is indigenous to Central Asia and the Indian subcontinent, and its uses for fabric and rope dates back to the Neolithic age in China and Japan. It is unclear when cannabis first became known for its psychoactive properties. The oldest archeological evidence for the burning of cannabis was found in Romanian kurgans dated 3,500 BC, and scholars suggest that the drug was first used in ritual ceremonies by Proto-Indo-European tribes living in the Pontic-Caspian steppe during the Chalcolithic period, a custom they eventually spread throughout western Eurasia during the Indo-European migrations. Some research suggests that the ancient Indo-Iranian drug soma, mentioned in the Vedas, sometimes contained cannabis. This is based on the discovery of a basin containing cannabis in a shrine of the second millennium BC in Turkmenistan.
Cannabis was known to the ancient Assyrians, who discovered its psychoactive properties through the Iranians. Using it in some religious ceremonies, they called it qunubu (meaning "way to produce smoke"), a probable origin of the modern word "cannabis". The Iranians also introduced cannabis to the Scythians, Thracians and Dacians, whose shamans (the kapnobatai—"those who walk on smoke/clouds") burned cannabis infructescences to induce trance. The plant was used in China before 2800 BC, and found therapeutic use in India by 1000 BC, where it was used in food and drink, including bhang.
Cannabis has an ancient history of ritual use and is found in pharmacological cults around the world. The earliest evidence of cannabis smoking has been found in the 2,500-year-old tombs of Jirzankal Cemetery in the Pamir Mountains in Western China, where cannabis residue were found in burners with charred pebbles possibly used during funeral rituals. Hemp seeds discovered by archaeologists at Pazyryk suggest early ceremonial practices like eating by the Scythians occurred during the 5th to 2nd century BC, confirming previous historical reports by Herodotus. It was used by Muslims in various Sufi orders as early as the Mamluk period, for example by the Qalandars. Smoking pipes uncovered in Ethiopia and carbon-dated to around c. AD 1320 were found to have traces of cannabis.
Following an 1836–1840 travel in North Africa and the Middle East, French physician Jacques-Joseph Moreau wrote on the psychological effects of cannabis use; he was a member of Paris' Club des Hashischins. In 1842, Irish physician William Brooke O'Shaughnessy, who had studied the drug while working as a medical officer in Bengal with the East India Company, brought a quantity of cannabis with him on his return to Britain, provoking renewed interest in the West. Examples of classic literature of the period featuring cannabis include Les paradis artificiels (1860) by Charles Baudelaire and The Hasheesh Eater (1857) by Fitz Hugh Ludlow.
Cannabis was criminalized in various countries beginning in the 19th century. The colonial government of Mauritius banned cannabis in 1840 over concerns on its effect on Indian indentured workers; the same occurred in Singapore in 1870. In the United States, the first restrictions on sale of cannabis came in 1906 (in the District of Columbia). Canada criminalized cannabis in The Opium and Narcotic Drug Act, 1923, before any reports of the use of the drug in Canada, but eventually legalized its consumption for recreational and medicinal purposes in 2018.
In 1925, a compromise was made at an international conference in The Hague about the International Opium Convention that banned exportation of "Indian hemp" to countries that had prohibited its use, and requiring importing countries to issue certificates approving the importation and stating that the shipment was required "exclusively for medical or scientific purposes". It also required parties to "exercise an effective control of such a nature as to prevent the illicit international traffic in Indian hemp and especially in the resin". In the United States in 1937, the Marihuana Tax Act was passed, and prohibited the production of hemp in addition to cannabis.
In 1972, the Dutch government divided drugs into more- and less-dangerous categories, with cannabis being in the lesser category. Accordingly, possession of 30 grams (1.1 oz) or less was made a misdemeanor. Cannabis has been available for recreational use in coffee shops since 1976. Cannabis products are only sold openly in certain local "coffeeshops" and possession of up to 5 grams (0.18 oz) for personal use is decriminalized, however: the police may still confiscate it, which often happens in car checks near the border. Other types of sales and transportation are not permitted, although the general approach toward cannabis was lenient even before official decriminalization.
In Uruguay, President Jose Mujica signed legislation to legalize recreational cannabis in December 2013, making Uruguay the first country in the modern era to legalize cannabis. In August 2014, Uruguay legalized growing up to six plants at home, as well as the formation of growing clubs, and a state-controlled marijuana dispensary regime.
As of 17 October 2018 when recreational use of cannabis was legalized in Canada, dietary supplements for human use and veterinary health products containing not more than 10 parts per million of THC extract were approved for marketing; Nabiximols (as Sativex) is used as a prescription drug in Canada.
The United Nations' World Drug Report stated that cannabis "was the world's most widely produced, trafficked, and consumed drug in the world in 2010", and estimated between 128 million and 238 million users globally in 2015.
The main component of cannabis is THC formed from decarboxylation of THCA. Raw leaf is not psychoactive because cannabinoids are in form of carboxylic acids. The major cannabinoid acids of raw cannabis are THCA, CBGA, CBDA, CBCA, CBGVA, THCVA, CBDVA, CBCVA. They are precursors to cannabinoids. On decarboxylation the following major cannabinoids THC, CBD, CBC, CBCV, CBDV, CBGV, THCV are formed. On more degradation CBN is formed. Cannabis is rich in terpenes too. The most common terpenes in cannabis are myrcene, limonene, caryophyllene, terpinolene, pinene, humulene, ocimene and linalool.
Society and culture
Since the beginning of the 20th century, most countries have enacted laws against the cultivation, possession or transfer of cannabis. These laws have had an adverse effect on cannabis cultivation for non-recreational purposes, but there are many regions where handling of cannabis is legal or licensed. Many jurisdictions have lessened the penalties for possession of small quantities of cannabis so that it is punished by confiscation and sometimes a fine, rather than imprisonment, focusing more on those who traffic the drug on the black market.
In some areas where cannabis use had been historically tolerated, new restrictions were instituted, such as the closing of cannabis coffee shops near the borders of the Netherlands, and closing of coffee shops near secondary schools in the Netherlands. In Copenhagen, Denmark in 2014, mayor Frank Jensen discussed possibilities for the city to legalize cannabis production and commerce.
Some jurisdictions use free voluntary treatment programs and/or mandatory treatment programs for frequent known users. Simple possession can carry long prison terms in some countries, particularly in East Asia, where the sale of cannabis may lead to a sentence of life in prison or even execution. Political parties, non-profit organizations, and causes based on the legalization of medical cannabis and/or legalizing the plant entirely (with some restrictions) have emerged in such countries as China and Thailand.
In December 2012, the U.S. state of Washington became the first state to officially legalize cannabis in a state law (Washington Initiative 502) (but still illegal by federal law), with the state of Colorado following close behind (Colorado Amendment 64). On 1 January 2013, the first marijuana "club" for private marijuana smoking (no buying or selling, however) was allowed for the first time in Colorado. The California Supreme Court decided in May 2013 that local governments can ban medical marijuana dispensaries despite a state law in California that permits the use of cannabis for medical purposes. At least 180 cities across California have enacted bans in recent years.
In December 2013, Uruguay became the first country to legalize growing, sale and use of cannabis. After a long delay in implementing the retail component of the law, in 2017 sixteen pharmacies were authorized to sell cannabis commercially. On 19 June 2018, the Canadian Senate passed a bill and the Prime Minister announced the effective legalization date as 17 October 2018. Canada is the second country to legalize the drug.
In November 2015, Uttarakhand became the first state of India to legalize the cultivation of hemp for industrial purposes. Usage within the Hindu and Buddhist cultures of the Indian subcontinent is common, with many street vendors in India openly selling products infused with cannabis, and traditional medical practitioners in Sri Lanka selling products infused with cannabis for recreational purposes and well as for religious celebrations. Indian laws criminalizing cannabis date back to the colonial period. India and Sri Lanka have allowed cannabis to be taken in the context of traditional culture for recreational/celebratory purposes and also for medicinal purposes.
On 17 October 2018, Canada legalized cannabis for recreational adult use making it the second country in the world to do so after Uruguay and the first G7 nation. The Canadian Licensed Producer system aims to become the Gold Standard in the world for safe and secure cannabis production, including provisions for a robust craft cannabis industry where many expect opportunities for experimenting with different strains. Laws around use vary from province to province including age limits, retail structure, and growing at home.
As the drug has increasingly been seen as a health issue instead of criminal behavior, marijuana has also been legalized or decriminalized in: Czech Republic, Colombia, Ecuador, Portugal, South Africa and Canada. Medical marijuana was legalized in Mexico in mid-2017; legislators plan to legalize its recreational use by late 2019.
Between 1973 and 1978, eleven states decriminalized marijuana. In 2001, Nevada reduced marijuana possession to a misdemeanor and since 2012, several other states have decriminalized and even legalized marijuana.
In 2018, almost half of the people in the United States had tried marijuana, 16% had used it in the past year, and 11% had used it in the past month. In 2014, daily marijuana use amongst US college students had reached its highest level since records began in 1980, rising from 3.5% in 2007 to 5.9% in 2014 and had surpassed daily cigarette use.
In the US, men are over twice as likely to use marijuana as women, and 18–29-year-olds are six times more likely to use as over-65-year-olds. In 2015, a record 44% of the US population has tried marijuana in their lifetime, an increase from 38% in 2013 and 33% in 1985.
Marijuana use in the United States is three times above the global average, but in line with other Western democracies. Forty-four percent of American 12th graders have tried the drug at least once, and the typical age of first-use is 16, similar to the typical age of first-use for alcohol but lower than the first-use age for other illicit drugs.
Sinsemilla (Spanish for "without seed") is the dried, seedless (i.e. parthenocarpic) infructescences of female cannabis plants. Because THC production drops off once pollination occurs, the male plants (which produce little THC themselves) are eliminated before they shed pollen to prevent pollination, thus inducing the development of parthenocarpic fruits gathered in dense infructescences. Advanced cultivation techniques such as hydroponics, cloning, high-intensity artificial lighting, and the sea of green method are frequently employed as a response (in part) to prohibition enforcement efforts that make outdoor cultivation more risky.
"Skunk" refers to several named strains of potent cannabis, grown through selective breeding and sometimes hydroponics. It is a cross-breed of Cannabis sativa and C. indica (although other strains of this mix exist in abundance). Skunk cannabis potency ranges usually from 6% to 15% and rarely as high as 20%. The average THC level in coffee shops in the Netherlands is about 18–19%.
The average levels of THC in cannabis sold in the United States rose dramatically between the 1970s and 2000. This is disputed for various reasons, and there is little consensus as to whether this is a fact or an artifact of poor testing methodologies. According to Daniel Forbes writing for slate.com, the relative strength of modern strains are likely skewed because undue weight is given to much more expensive and potent, but less prevalent, samples. Some suggest that results are skewed by older testing methods that included low-THC-content plant material such as leaves in the samples, which are excluded in contemporary tests. Others believe that modern strains actually are significantly more potent than older ones.
The price or street value of cannabis varies widely depending on geographic area and potency. Prices and overall markets have also varied considerably over time.
- In 1997, cannabis was estimated to be overall the number four value crop in the US, and number one or two in many states, including California, New York, and Florida. This estimate is based on a value to growers of ~60% of retail value, or $3,000 per pound ($6,600/kg).
- In 2006, cannabis was estimated to have been a $36 billion market. This estimate has been challenged as exaggerated. The UN World Drug Report (2008) estimated that 2006 street prices in the US and Canada ranged from about US$8.8 to $25 per gram (approximately $250 to $700 per ounce), depending on quality. Typical U.S. retail prices were $10–15 per gram (approximately $280–420 per ounce).
- In 2017, the U.S. was estimated to constitute 90% of the worldwide $9.5 billion trade in cannabis.
After some U.S. states legalized cannabis, street prices began to drop. In Colorado, the price of smokable buds (infructescences) dropped 40 percent between 2014 and 2019, from $200 per ounce to $120 per ounce ($7 per gram to $4.19 per gram).
The European Monitoring Centre for Drugs and Drug Addiction reports that typical retail prices in Europe for cannabis varied from €2 to €20 per gram in 2008, with a majority of European countries reporting prices in the range €4–10.
The gateway hypothesis states that cannabis use increases the probability of trying "harder" drugs. The hypothesis has been hotly debated as it is regarded by some as the primary rationale for the United States prohibition on cannabis use. A Pew Research Center poll found that political opposition to marijuana use was significantly associated with concerns about the health effects and whether legalization would increase marijuana use by children.
Some studies state that while there is no proof for the gateway hypothesis, young cannabis users should still be considered as a risk group for intervention programs. Other findings indicate that hard drug users are likely to be poly-drug users, and that interventions must address the use of multiple drugs instead of a single hard drug. Almost two-thirds of the poly drug users in the 2009-2010 Scottish Crime and Justice Survey used cannabis.
The gateway effect may appear due to social factors involved in using any illegal drug. Because of the illegal status of cannabis, its consumers are likely to find themselves in situations allowing them to acquaint with individuals using or selling other illegal drugs. Studies have shown that alcohol and tobacco may additionally be regarded as gateway drugs; however, a more parsimonious explanation could be that cannabis is simply more readily available (and at an earlier age) than illegal hard drugs. In turn, alcohol and tobacco are typically easier to obtain at an earlier age than is cannabis (though the reverse may be true in some areas), thus leading to the "gateway sequence" in those individuals, since they are most likely to experiment with any drug offered.
A related alternative to the gateway hypothesis is the common liability to addiction (CLA) theory. It states that some individuals are, for various reasons, willing to try multiple recreational substances. The "gateway" drugs are merely those that are (usually) available at an earlier age than the harder drugs. Researchers have noted in an extensive review that it is dangerous to present the sequence of events described in gateway "theory" in causative terms as this hinders both research and intervention.
In 2020, the National Institute on Drug Abuse released a study backing allegations that marijuana is a gateway to harder drugs, though not for the majority of marijuana users. The National Institute on Drug Abuse determined that marijuana use is "likely to precede use of other licit and illicit substances" and that "adults who reported marijuana use during the first wave of the survey were more likely than adults who did not use marijuana to develop an alcohol use disorder within 3 years; people who used marijuana and already had an alcohol use disorder at the outset were at greater risk of their alcohol use disorder worsening. Marijuana use is also linked to other substance use disorders including nicotine addiction." It also reported that "These findings are consistent with the idea of marijuana as a "gateway drug." However, the majority of people who use marijuana do not go on to use other, "harder" substances. Also, cross-sensitization is not unique to marijuana. Alcohol and nicotine also prime the brain for a heightened response to other drugs and are, like marijuana, also typically used before a person progresses to other, more harmful substances."
Cannabis research is challenging since the plant is illegal in most countries. Research-grade samples of the drug are difficult to obtain for research purposes, unless granted under authority of national regulatory agencies, such as the US Food and Drug Administration.
There are also other difficulties in researching the effects of cannabis. Many people who smoke cannabis also smoke tobacco. This causes confounding factors, where questions arise as to whether the tobacco, the cannabis, or both that have caused a cancer. Another difficulty researchers have is in recruiting people who smoke cannabis into studies. Because cannabis is an illegal drug in many countries, people may be reluctant to take part in research, and if they do agree to take part, they may not say how much cannabis they actually smoke.
A 2015 review found that the use of high CBD-to-THC strains of cannabis showed significantly fewer positive symptoms, such as delusions and hallucinations, better cognitive function and both lower risk for developing psychosis, as well as a later age of onset of the illness, compared to cannabis with low CBD-to-THC ratios. Reviews in 2019 found that research was insufficient to determine the safety and efficacy of using cannabis to treat schizophrenia, psychosis, or other mental disorders. There is preliminary evidence that cannabis interferes with the anticoagulant properties of prescription drugs used for treating blood clots. As of 2019[update], the mechanisms for the anti-inflammatory and possible pain relieving effects of cannabis were not defined, and there were no governmental regulatory approvals or clinical practices for use of cannabis as a drug.
Currently, Uruguay and Canada are the only countries that have fully legalized the consumption and sale of recreational cannabis nationwide. In the United States, 17 states, 2 territories, and the District of Columbia have legalized the recreational use of cannabis – though the drug remains illegal at the federal level. Laws vary from state to state when it comes to the commercial sale. Court rulings in Georgia and South Africa have led to the legalization of cannabis consumption, but not legal sales. A policy of limited enforcement has also been adopted in many countries, in particular Spain and the Netherlands where the sale of cannabis is tolerated at licensed establishments. Contrary to popular belief, cannabis is not legal in the Netherlands but it has been decriminalized since the 1970s. Lebanon has recently become the first Arab country to legalize the plantation of cannabis for medical use.
Penalties for illegal recreational use ranges from confiscation or small fines to jail time and even death. In some countries citizens can be punished if they have used the drug in another country, including Singapore and South Korea.
- Occupational health concerns of cannabis use
- Green rush
- List of books about cannabis
- List of cannabis columns
- Also referred to as marihuana, pot, weed, dope, and ganja //, among many other nicknames (grass, herb, skunk, Mary Jane, etc.).
- Psychotic episodes are well-documented and typically resolve within minutes or hours, while symptoms may last longer. The use of a single joint can temporarily induce some psychiatric symptoms.
- A 2016 review also found a statistically significant increase in crash risk associated with marijuana use, but noted that this risk was "of low to medium magnitude." The increase in risk of motor vehicle crash for cannabis use is between 2 and 3 times relative to baseline, whereas that for comparable doses of alcohol is between 6 and 15 times.
- Advocates of legalizing marijuana for recreational use, such as Illinois state Senator Heather Steans, has said that legalizing it would help reduce such hazardous added drugs: "Over 95 percent are buying it on the black market. You don't know what you're buying. It's not a safe product. We've seen it laced with rat poison, fentanyl, all sorts of things. It's funding the cartels and other criminal activity."
- "marijuana noun – Definition, pictures, pronunciation and usage notes | Oxford Advanced Learner's Dictionary at OxfordLearnersDictionaries.com". www.oxfordlearnersdictionaries.com. Retrieved 18 April 2019.
- ElSohly MA (2007). Marijuana and the Cannabinoids. Springer. p. 8. ISBN 978-1-59259-947-9.
- United Nations. "World Drug Report 2013" (PDF). United Nations Office on Drugs and Crime. Retrieved 13 December 2014.
- "Medical Use of Marijuana". Health Canada. Retrieved 12 January 2015.
- "New Colombia Resources Inc Subsidiary, Sannabis, Produces First Batch of Medical Marijuana Based Products in Colombia to Fill Back Orders". prnewswire.com. PR Newswire. Retrieved 12 January 2015.
- Moussaoui R (25 November 2013). "Lebanon cannabis trade thrives in shadow of Syrian war". AFP.
- Garelli SL (25 November 2008). "Mexico, Paraguay top pot producers, U.N. report says". CNN International. Retrieved 28 September 2013.
- Jackman, Robert (12 January 2019). "How Britain became the world's largest exporter of medical marijuana". The Spectator. Retrieved 27 December 2019.
- "Pot – Definition". Merriam-Webster Dictionary. Retrieved 9 October 2012.
- "Weed – Definition". Merriam-Webster Dictionary. Retrieved 9 October 2012.
- "Dope – Definition". Merriam-Webster Dictionary. Retrieved 17 July 2017.
- "Ganja – Definition". Merriam-Webster Dictionary. Retrieved 17 July 2017.
- Ruiz P, Strain EC (2011). Substance Abuse: A Comprehensive Textbook. Lippincott Williams & Wilkins. p. 214. ISBN 978-1-60547-277-5.
- "Grass – Definition". Merriam-Webster Dictionary. Retrieved 9 October 2012.
- "Herb – Definition". Merriam-Webster Dictionary. Retrieved 9 October 2012.
- "Skunk – Definition". American Heritage Dictionary of the English Language. Retrieved 17 July 2017.
- "Mary Jane – Definition". Merriam-Webster Dictionary. Retrieved 17 July 2017.
- Vij (2012). Textbook Of Forensic Medicine And Toxicology: Principles And Practice. Elsevier India. p. 672. ISBN 978-81-312-1129-8.See also article on Marijuana as a word.
- Shorter Oxford English Dictionary (6th ed.), Oxford University Press, 2007, ISBN 978-0-19-920687-2
- Spanish Word Histories and Mysteries: English Words That Come From Spanish. Houghton Mifflin Harcourt. 2007. p. 142. ISBN 978-0-547-35021-9.
- Russo EB (2013). Cannabis and Cannabinoids: Pharmacology, Toxicology, and Therapeutic Potential. Routledge. p. 28. ISBN 978-1-136-61493-4.
- Newton DE (2013). Marijuana: a reference handbook. Santa Barbara, Calif.: ABC-CLIO. p. 7. ISBN 9781610691499.
- D'Souza DC, Sewell RA, Ranganathan M (October 2009). "Cannabis and psychosis/schizophrenia: human studies". European Archives of Psychiatry and Clinical Neuroscience. 259 (7): 413–31. doi:10.1007/s00406-009-0024-2. PMC 2864503. PMID 19609589.
- "DrugFacts: Marijuana". National Institute on Drug Abuse, US National Institutes of Health. 1 December 2019. Retrieved 20 January 2020.
- Osborne GB, Fogel C (2008). "Understanding the motivations for recreational marijuana use among adult Canadians" (PDF). Substance Use & Misuse. 43 (3–4): 539–72, discussion 573–9, 585–7. doi:10.1080/10826080701884911. PMID 18365950. S2CID 31053594.
- "Marijuana: Factsheets: Appetite". Adai.uw.edu. Retrieved 12 July 2013.
- Riviello RJ (2010). Manual of forensic emergency medicine : a guide for clinicians. Sudbury, Mass.: Jones and Bartlett Publishers. p. 41. ISBN 9780763744625.
- Leweke FM, Mueller JK, Lange B, Rohleder C (April 2016). "Therapeutic Potential of Cannabinoids in Psychosis". Biological Psychiatry. 79 (7): 604–12. doi:10.1016/j.biopsych.2015.11.018. PMID 26852073. S2CID 24160677.
Epidemiological data indicate a strong relationship between cannabis use and psychosis and schizophrenia beyond transient intoxication with an increased risk of any psychotic outcome in individuals who had ever used cannabis
- Ortiz-Medina, MB; Perea, M; Torales, J; Ventriglio, A; Vitrani, G; Aguilar, L; Roncero, C (November 2018). "Cannabis consumption and psychosis or schizophrenia development". The International Journal of Social Psychiatry. 64 (7): 690–704. doi:10.1177/0020764018801690. PMID 30442059. S2CID 53563635.
Cannabis use doubles the risk of developing psychosis in vulnerable people.
- Ksir C, Hart CL (February 2016). "Cannabis and Psychosis: a Critical Overview of the Relationship". Current Psychiatry Reports. 18 (2): 12. doi:10.1007/s11920-015-0657-y. PMID 26781550. S2CID 36538598.
- "Marijuana intoxication: MedlinePlus Medical Encyclopedia". Nlm.nih.gov. Retrieved 12 July 2013.
- Crippa JA, Zuardi AW, Martín-Santos R, Bhattacharyya S, Atakan Z, McGuire P, Fusar-Poli P (October 2009). "Cannabis and anxiety: a critical review of the evidence". Human Psychopharmacology. 24 (7): 515–23. doi:10.1002/hup.1048. PMID 19693792. S2CID 13544234.
- "Commonly Abused Drugs Charts: Marijuana (Cannabis)". National Institute on Drug Abuse, US National Institutes of Health. 22 July 2019. Retrieved 20 January 2020.
- "Status and Trend Analysis of Illict [sic] Drug Markets" (PDF). World Drug Report 2015. p. 23. Retrieved 26 June 2015.
- "UNODC Statistics Online". data.unodc.org. Retrieved 9 September 2018.
- Booth M (2003). Cannabis: A History. Transworld. p. 36. ISBN 978-1-4090-8489-1.
- Donahue, Michelle (12 June 2019). "Earliest evidence for cannabis smoking discovered in ancient tombs". National Geographic.
- "Cannabis: Legal Status". Erowid.org. Retrieved 30 October 2011.
- UNODC. World Drug Report 2010. United Nations Publication. p. 198. Retrieved 19 July 2010.
- Lemon, Jason (17 October 2018). "Where Is Weed Legal Around The World? You Can Now Officially Smoke Pot In Canada". Newsweek. Retrieved 7 May 2019.
- "Marijuana Overview". National Conference of State Legislatures. Retrieved 29 August 2019.
- Williams, Sean (21 July 2018). "These 30 Countries Have Legalized Medical Marijuana in Some Capacity". The Motley Fool. Retrieved 7 May 2019.
- Murnion B (December 2015). "Medicinal cannabis". Australian Prescriber. 38 (6): 212–5. doi:10.18773/austprescr.2015.072. PMC 4674028. PMID 26843715.
- "What is medical marijuana?". National Institute of Drug Abuse. July 2015. Retrieved 19 April 2016.
The term medical marijuana refers to using the whole unprocessed marijuana plant or its basic extracts to treat a disease or symptom.
- "Release the strains". Nature Medicine. 21 (9): 963. September 2015. doi:10.1038/nm.3946. PMID 26340110.
- Borgelt LM, Franson KL, Nussbaum AM, Wang GS (February 2013). "The pharmacologic and clinical effects of medical cannabis". Pharmacotherapy. 33 (2): 195–209. CiteSeerX 10.1.1.1017.1935. doi:10.1002/phar.1187. PMID 23386598. S2CID 8503107.
- Whiting PF, Wolff RF, Deshpande S, Di Nisio M, Duffy S, Hernandez AV, Keurentjes JC, Lang S, Misso K, Ryder S, Schmidlkofer S, Westwood M, Kleijnen J (23 June 2015). "Cannabinoids for Medical Use: A Systematic Review and Meta-analysis". JAMA. 313 (24): 2456–73. doi:10.1001/jama.2015.6358. hdl:10757/558499. PMID 26103030.
- Jensen B, Chen J, Furnish T, Wallace M (October 2015). "Medical Marijuana and Chronic Pain: a Review of Basic Science and Clinical Evidence". Current Pain and Headache Reports. 19 (10): 50. doi:10.1007/s11916-015-0524-x. PMID 26325482. S2CID 9110606.
- Onaivi ES, Sugiura T, Di Marzo V (2005). Endocannabinoids: The Brain and Body's Marijuana and Beyond. Taylor & Francis. p. 58. ISBN 978-0-415-30008-7.
- "Medication-Associated Depersonalization Symptoms".
- Shufman E, Lerner A, Witztum E (April 2005). "[Depersonalization after withdrawal from cannabis usage]" (PDF). Harefuah (in Hebrew). 144 (4): 249–51, 303. PMID 15889607. Archived from the original (PDF) on 30 April 2005.
- Johnson BA (February 1990). "Psychopharmacological effects of cannabis". British Journal of Hospital Medicine. 43 (2): 114–6, 118–20, 122. PMID 2178712.
- Hall W, Pacula RL (2003). Cannabis Use and Dependence: Public Health and Public Policy. Cambridge University Press. p. 38. ISBN 978-0-521-80024-2.
- Mathre ML, ed. (1997). Cannabis in Medical Practice: A Legal, Historical, and Pharmacological Overview of the Therapeutic Use of Marijuana. University of Virginia Medical Center. pp. 144–. ISBN 978-0-7864-8390-7.
- Riedel G, Davies SN (2005). "Cannabinoid function in learning, memory and plasticity". Cannabinoids. Handbook of Experimental Pharmacology. 168. pp. 445–77. doi:10.1007/3-540-26573-2_15. ISBN 978-3-540-22565-2. PMID 16596784.
- Barceloux DG (3 February 2012). "Chapter 60: Marijuana (Cannabis sativa L.) and synthetic cannabinoids". Medical Toxicology of Drug Abuse: Synthesized Chemicals and Psychoactive Plants. John Wiley & Sons. pp. 910–. ISBN 978-1-118-10605-1. Retrieved 14 July 2013.
- Goldenberg M, IsHak WW, Danovitch I (January 2017). "Quality of life and recreational cannabis use". The American Journal on Addictions. 26 (1): 8–25. doi:10.1111/ajad.12486. PMID 28000973. S2CID 40707053.
- Souza RS, Albuquerque UP, Monteiro JM, de Amorim EL (2008). "Brazilian Archives of Biology and Technology – Jurema-Preta (Mimosa tenuiflora [Willd.] Poir.): a review of its traditional use, phytochemistry and pharmacology". Brazilian Archives of Biology and Technology. 51 (5): 937–947. doi:10.1590/S1516-89132008000500010.
- Courtwright D (2001). Forces of Habit: Drugs and the Making of the Modern World. Harvard Univ. Press. p. 39. ISBN 978-0-674-00458-0.
- Golub A (2012). The Cultural/Subcultural Contexts of Marijuana Use at the Turn of the Twenty-First Century. Routledge. p. 82. ISBN 978-1-136-44627-6.
- Why Does Cannabis Have to be Heated?
- Tasman A, Kay J, Lieberman JA, First MB, Maj M (2011). Psychiatry. John Wiley & Sons. p. 9. ISBN 978-1-119-96540-4.
- Rosenthal E (2002). Ask Ed: Marijuana Gold: Trash to Stash. Perseus Books Group. p. 15. ISBN 978-1-936807-02-4.
- "Cannabis and Cannabis Extracts: Greater Than the Sum of Their Parts?" (PDF). Cannabis-med.org. Retrieved 7 April 2014.
- Dronabinol in the ChemIDplus database
- Gieringer D, Rosenthal E (2008). Marijuana medical handbook: practical guide to therapeutic uses of marijuana. QUICK AMER Publishing Company. p. 182. ISBN 978-0-932551-86-3.
- "Health products containing cannabis or for use with cannabis: Guidance for the Cannabis Act, the Food and Drugs Act, and related regulations". Government of Canada. 11 July 2018. Retrieved 19 October 2018.
- Nutt D, King LA, Saulsbury W, Blakemore C (March 2007). "Development of a rational scale to assess the harm of drugs of potential misuse". Lancet. 369 (9566): 1047–53. doi:10.1016/s0140-6736(07)60464-4. PMID 17382831. S2CID 5903121.
- "Sativex Oral Mucosal Spray Public Assessment Report. Decentralized Procedure" (PDF). United Kingdom Medicines and Healthcare Products Regulatory Agency. p. 93. Retrieved 7 May 2015.
There is clear evidence that recreational cannabis can produce a transient toxic psychosis in larger doses or in susceptible individuals, which is said to characteristically resolve within a week or so of absence (Johns 2001). Transient psychotic episodes as a component of acute intoxication are well-documented (Hall et al 1994)
- Hunt, Katie (17 March 2020). "Single cannabis joint linked with temporary psychiatric symptoms, review finds". CNN. Retrieved 21 March 2020.
- Hall W, Solowij N (November 1998). "Adverse effects of cannabis". Lancet. 352 (9140): 1611–6. doi:10.1016/S0140-6736(98)05021-1. PMID 9843121. S2CID 16313727.
- Oltmanns T, Emery R (2015). Abnormal Psychology. New Jersey: Pearson. p. 294. ISBN 978-0205970742.
- Abuse, National Institute on Drug. "Does marijuana use affect driving?". www.drugabuse.gov. Retrieved 18 December 2019.
- Li MC, Brady JE, DiMaggio CJ, Lusardi AR, Tzong KY, Li G (4 October 2011). "Marijuana use and motor vehicle crashes". Epidemiologic Reviews. 34 (1): 65–72. doi:10.1093/epirev/mxr017. PMC 3276316. PMID 21976636.
- Rogeberg O, Elvik R (August 2016). "The effects of cannabis intoxication on motor vehicle collision revisited and revised". Addiction. 111 (8): 1348–59. doi:10.1111/add.13347. PMID 26878835.
- Hall W (January 2015). "What has research over the past two decades revealed about the adverse health effects of recreational cannabis use?" (PDF). Addiction. 110 (1): 19–35. doi:10.1111/add.12703. PMID 25287883.
- "National Estimates of Drug-Related Emergency Department Visits" (PDF). Drug Abuse Warning Network. U.S. Department of Health and Human Services. 2011. Retrieved 8 May 2015.
- "National Estimates of Drug-related Emergency Department Visits, 2004 – 2011". Drug Abuse Warning Network. U.S. Department of Health and Human Services.
- Volkow ND, Baler RD, Compton WM, Weiss SR (June 2014). "Adverse health effects of marijuana use". The New England Journal of Medicine. 370 (23): 2219–27. doi:10.1056/NEJMra1402309. PMC 4827335. PMID 24897085.
- "Growing Array of Street Drugs Now Laced with Fentanyl", MedPageToday, 17 July 2018
- "What Can Marijuana Be Laced With?", American Addiction Centers, updated 26 November 2018
- "Is the opioid epidemic now the fentanyl epidemic?", The Baltimore Sun, 7 December 2018
- "Medical officials oppose effort to legalize recreational use of marijuana", State Journal-Register, (Springfield, IL), 15 December 2018
- Gordon AJ, Conley JW, Gordon JM (December 2013). "Medical consequences of marijuana use: a review of current literature". Current Psychiatry Reports. 15 (12): 419. doi:10.1007/s11920-013-0419-7. PMID 24234874. S2CID 29063282.
- Nomura, Y; Marks, DJ; Halperin, JM (September 2010). "Prenatal exposure to maternal and paternal smoking on attention deficit hyperactivity disorders symptoms and diagnosis in offspring". The Journal of Nervous and Mental Disease. 198 (9): 672–8. doi:10.1097/NMD.0b013e3181ef3489. PMC 3124822. PMID 20823730.
- American College of Obstetricians Gynecologists Committee on Obstetric Practice (July 2015). "Committee Opinion No. 637: Marijuana Use During Pregnancy and Lactation". Obstetrics and Gynecology. 126 (1): 234–8. doi:10.1097/01.AOG.0000467192.89321.a6. PMID 26241291.
- Gunn JK, Rosales CB, Center KE, Nuñez A, Gibson SJ, Christ C, Ehiri JE (April 2016). "Prenatal exposure to cannabis and maternal and child health outcomes: a systematic review and meta-analysis". BMJ Open. 6 (4): e009986. doi:10.1136/bmjopen-2015-009986. PMC 4823436. PMID 27048634.
- Conner SN, Bedell V, Lipsey K, Macones GA, Cahill AG, Tuuli MG (October 2016). "Maternal Marijuana Use and Adverse Neonatal Outcomes: A Systematic Review and Meta-analysis". Obstetrics and Gynecology. 128 (4): 713–23. doi:10.1097/AOG.0000000000001649. PMID 27607879. S2CID 10697253.
- Subbaraman MS (8 January 2014). "Can cannabis be considered a substitute medication for alcohol?". Alcohol and Alcoholism. 49 (3): 292–8. doi:10.1093/alcalc/agt182. PMC 3992908. PMID 24402247.
- Armentano, Paul (5 February 2019). "Marijuana access is associated with decreased use of alcohol, tobacco and other prescription drugs". The Hill.
- Maisto S, Galizio M, Connors G (2014). Drug Use and Abuse. Cengage Learning. p. 278. ISBN 978-1-305-17759-8.
- Owen KP, Sutter ME, Albertson TE (February 2014). "Marijuana: respiratory tract effects". Clinical Reviews in Allergy & Immunology. 46 (1): 65–81. doi:10.1007/s12016-013-8374-y. PMID 23715638. S2CID 23823391.
- Tetrault JM, Crothers K, Moore BA, Mehra R, Concato J, Fiellin DA (February 2007). "Effects of marijuana smoking on pulmonary function and respiratory complications: a systematic review". Archives of Internal Medicine. 167 (3): 221–8. doi:10.1001/archinte.167.3.221. PMC 2720277. PMID 17296876.
- Sorensen CJ, DeSanto K, Borgelt L, Phillips KT, Monte AA (March 2017). "Cannabinoid Hyperemesis Syndrome: Diagnosis, Pathophysiology, and Treatment-a Systematic Review". Journal of Medical Toxicology. 13 (1): 71–87. doi:10.1007/s13181-016-0595-z. PMC 5330965. PMID 28000146.
- Hashibe M, Straif K, Tashkin DP, Morgenstern H, Greenland S, Zhang ZF (April 2005). "Epidemiologic review of marijuana use and cancer risk". Alcohol. 35 (3): 265–75. doi:10.1016/j.alcohol.2005.04.008. PMID 16054989.
- "Does smoking cannabis cause cancer?". Cancer Research UK. 20 September 2010. Archived from the original on 29 July 2012. Retrieved 9 January 2013.
- Tashkin, Donald (March 1997). "Effects of marijuana on the lung and its immune defenses". UCLA School of Medicine. Retrieved 23 June 2012.
- Gates P, Jaffe A, Copeland J (July 2014). "Cannabis smoking and respiratory health: consideration of the literature". Respirology. 19 (5): 655–62. doi:10.1111/resp.12298. PMID 24831571. S2CID 29423964.
- Huang YH, Zhang ZF, Tashkin DP, Feng B, Straif K, Hashibe M (January 2015). "An epidemiologic review of marijuana and cancer: an update". Cancer Epidemiology, Biomarkers & Prevention. 24 (1): 15–31. doi:10.1158/1055-9965.EPI-14-1026. PMC 4302404. PMID 25587109.
- Tashkin DP (June 2013). "Effects of marijuana smoking on the lung" (PDF). Annals of the American Thoracic Society. 10 (3): 239–47. doi:10.1513/annalsats.201212-127fr. PMID 23802821. S2CID 20615545. Archived from the original (PDF) on 20 February 2020.
- Gurney J, Shaw C, Stanley J, Signal V, Sarfati D (November 2015). "Cannabis exposure and risk of testicular cancer: a systematic review and meta-analysis". BMC Cancer. 15 (1): 897. doi:10.1186/s12885-015-1905-6. PMC 4642772. PMID 26560314.
- de Carvalho MF, Dourado MR, Fernandes IB, Araújo CT, Mesquita AT, Ramos-Jorge ML (December 2015). "Head and neck cancer among marijuana users: a meta-analysis of matched case-control studies". Archives of Oral Biology. 60 (12): 1750–5. doi:10.1016/j.archoralbio.2015.09.009. PMID 26433192.
- Loflin M, Earleywine M (2015). "No smoke, no fire: What the initial literature suggests regarding vapourized cannabis and respiratory risk". Canadian Journal of Respiratory Therapy. 51 (1): 7–9. PMC 4456813. PMID 26078621.
- Riecher-Rössler A (2014). Comorbidity of Mental and Physical Disorders. Karger Medical and Scientific Publishers. p. 88. ISBN 978-3-318-02604-7.
- Ravi D, Ghasemiesfe M, Korenstein D, Cascino T, Keyhani S (February 2018). "Associations Between Marijuana Use and Cardiovascular Risk Factors and Outcomes: A Systematic Review". Annals of Internal Medicine. 168 (3): 187–194. doi:10.7326/M17-1548. PMC 6157910. PMID 29357394.
- Thomas G, Kloner RA, Rezkalla S (January 2014). "Adverse cardiovascular, cerebrovascular, and peripheral vascular effects of marijuana inhalation: what cardiologists need to know". The American Journal of Cardiology. 113 (1): 187–90. doi:10.1016/j.amjcard.2013.09.042. PMID 24176069.
- Franz CA, Frishman WH (9 February 2016). "Marijuana Use and Cardiovascular Disease". Cardiology in Review. 24 (4): 158–62. doi:10.1097/CRD.0000000000000103. PMID 26886465. S2CID 205566342.
- Rocchetti M, Crescini A, Borgwardt S, Caverzasi E, Politi P, Atakan Z, Fusar-Poli P (November 2013). "Is cannabis neurotoxic for the healthy brain? A meta-analytical review of structural brain alterations in non-psychotic users". Psychiatry and Clinical Neurosciences. 67 (7): 483–92. doi:10.1111/pcn.12085. PMID 24118193. S2CID 8245635.
- Batalla A, Bhattacharyya S, Yücel M, Fusar-Poli P, Crippa JA, Nogué S, Torrens M, Pujol J, Farré M, Martin-Santos R (2013). "Structural and functional imaging studies in chronic cannabis users: a systematic review of adolescent and adult findings". PLOS ONE. 8 (2): e55821. Bibcode:2013PLoSO...855821B. doi:10.1371/journal.pone.0055821. PMC 3563634. PMID 23390554.
The most consistently reported brain alteration was reduced hippocampal volume which was shown to persist even after several months of abstinence in one study and also to be related to the amount of cannabis use Other frequently reported morphological brain alterations related to chronic cannabis use were reported in the amygdala the cerebellum and the frontal cortex...These findings may be interpreted as reflecting neuroadaptation, perhaps indicating the recruitment of additional regions as a compensatory mechanism to maintain normal cognitive performance in response to chronic cannabis exposure, particularly within the prefrontal cortex area.
- Weinstein A, Livny A, Weizman A (2016). "Brain Imaging Studies on the Cognitive, Pharmacological and Neurobiological Effects of Cannabis in Humans: Evidence from Studies of Adult Users". Current Pharmaceutical Design. 22 (42): 6366–6379. doi:10.2174/1381612822666160822151323. PMID 27549374.
1)The studies reviewed so far demonstrated that chronic cannabis use has been associated with a volume reduction of the hippocampus...3)The overall conclusion arising from these studies is that recent cannabis users may experience subtle neurophysiological deficits while performing on working memory tasks, and that they compensate for these deficits by "working harder" by using additional brain regions to meet the demands of the task.
- Blest-Hopley G, Giampietro V, Bhattacharyya S (May 2018). "Residual effects of cannabis use in adolescent and adult brains – A meta-analysis of fMRI studies" (PDF). Neuroscience and Biobehavioral Reviews. 88: 26–41. doi:10.1016/j.neubiorev.2018.03.008. PMID 29535069. S2CID 4402954.
This may reflect the multitude of cognitive tasks employed by the various studies included in these meta-analyses, all of which involved performing a task thereby requiring the participant to reorient their attention and attempt to solve the problem at hand and suggest that greater engagement of this region indicates less efficient cognitive performance in cannabis users in general, irrespective of their age.
- Curran HV, Freeman TP, Mokrysz C, Lewis DA, Morgan CJ, Parsons LH (May 2016). "Keep off the grass? Cannabis, cognition and addiction" (PDF). Nature Reviews. Neuroscience. 17 (5): 293–306. doi:10.1038/nrn.2016.28. hdl:10871/24746. PMID 27052382. S2CID 1685727.
- Parsons LH, Hurd YL (October 2015). "Endocannabinoid signalling in reward and addiction". Nature Reviews. Neuroscience. 16 (10): 579–94. doi:10.1038/nrn4004. PMC 4652927. PMID 26373473.
- Zehra A, Burns J, Liu CK, Manza P, Wiers CE, Volkow ND, Wang GJ (March 2018). "Cannabis Addiction and the Brain: a Review". Journal of Neuroimmune Pharmacology. 13 (4): 438–452. doi:10.1007/s11481-018-9782-9. PMC 6223748. PMID 29556883.
- Colizzi M, McGuire P, Pertwee RG, Bhattacharyya S (May 2016). "Effect of cannabis on glutamate signalling in the brain: A systematic review of human and animal evidence". Neuroscience and Biobehavioral Reviews. 64: 359–81. doi:10.1016/j.neubiorev.2016.03.010. PMID 26987641. S2CID 24043856.
- Schoeler T, Kambeitz J, Behlke I, Murray R, Bhattacharyya S (January 2016). "The effects of cannabis on memory function in users with and without psychotic disorder: findings from a combined meta-analysis". Psychological Medicine. 46 (1): 177–88. doi:10.1017/S0033291715001646. PMID 26353818.
- Schreiner AM, Dunn ME (October 2012). "Residual effects of cannabis use on neurocognitive performance after prolonged abstinence: a meta-analysis" (PDF). Experimental and Clinical Psychopharmacology. 20 (5): 420–429. doi:10.1037/a0029117. PMID 22731735. S2CID 207618350. Archived from the original (PDF) on 2 March 2019.
Therefore, results indicate evidence for small neurocognitive effects that persist after the period of acute intoxication...As hypothesized, the meta-analysis conducted on studies eval- uating users after at least 25 days of abstention found no residual effects on cognitive performance...These results fail to support the idea that heavy cannabis use may result in long-term, persistent effects on neuropsychological functioning.
- Gonzalez R, Carey C, Grant I (November 2002). "Nonacute (residual) neuropsychological effects of cannabis use: a qualitative analysis and systematic review". Journal of Clinical Pharmacology. 42 (S1): 48S–57S. doi:10.1002/j.1552-4604.2002.tb06003.x. PMID 12412836. S2CID 37826919.
- Crean RD, Crane NA, Mason BJ (March 2011). "An evidence based review of acute and long-term effects of cannabis use on executive cognitive functions". Journal of Addiction Medicine. 5 (1): 1–8. doi:10.1097/ADM.0b013e31820c23fa. PMC 3037578. PMID 21321675.
Cannabis appears to continue to exert impairing effects in executive functions even after 3 weeks of abstinence and beyond. While basic attentional and working memory abilities are largely restored, the most enduring and detectable deficits are seen in decision-making, concept formation and planning.
- Broyd SJ, van Hell HH, Beale C, Yücel M, Solowij N (April 2016). "Acute and Chronic Effects of Cannabinoids on Human Cognition-A Systematic Review". Biological Psychiatry. 79 (7): 557–67. doi:10.1016/j.biopsych.2015.12.002. PMID 26858214. S2CID 9858298.
- Ganzer F, Bröning S, Kraft S, Sack PM, Thomasius R (June 2016). "Weighing the Evidence: A Systematic Review on Long-Term Neurocognitive Effects of Cannabis Use in Abstinent Adolescents and Adults". Neuropsychology Review. 26 (2): 186–222. doi:10.1007/s11065-016-9316-2. PMID 27125202. S2CID 4335379.
- Marconi A, Di Forti M, Lewis CM, Murray RM, Vassos E (September 2016). "Meta-analysis of the Association Between the Level of Cannabis Use and Risk of Psychosis". Schizophrenia Bulletin. 42 (5): 1262–9. doi:10.1093/schbul/sbw003. PMC 4988731. PMID 26884547.
- Moore TH, Zammit S, Lingford-Hughes A, Barnes TR, Jones PB, Burke M, Lewis G (July 2007). "Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review" (PDF). Lancet. 370 (9584): 319–28. doi:10.1016/S0140-6736(07)61162-3. PMID 17662880. S2CID 41595474.
- Semple DM, McIntosh AM, Lawrie SM (March 2005). "Cannabis as a risk factor for psychosis: systematic review". Journal of Psychopharmacology. 19 (2): 187–94. doi:10.1177/0269881105049040. PMID 15871146. S2CID 44651274.
- Large M, Sharma S, Compton MT, Slade T, Nielssen O (June 2011). "Cannabis use and earlier onset of psychosis: a systematic meta-analysis". Archives of General Psychiatry. 68 (6): 555–61. doi:10.1001/archgenpsychiatry.2011.5. PMID 21300939.
- McLaren JA, Silins E, Hutchinson D, Mattick RP, Hall W (January 2010). "Assessing evidence for a causal link between cannabis and psychosis: a review of cohort studies". The International Journal on Drug Policy. 21 (1): 10–9. doi:10.1016/j.drugpo.2009.09.001. PMID 19783132.
The contentious issue of whether cannabis use can cause serious psychotic disorders that would not otherwise have occurred cannot be answered based on the existing data
- Carey, Benedict (17 January 2019). "Does Marijuana Use Cause Schizophrenia?". The New York Times. ISSN 0362-4331. Retrieved 23 January 2019.
- Calabria B, Degenhardt L, Hall W, Lynskey M (May 2010). "Does cannabis use increase the risk of death? Systematic review of epidemiological evidence on adverse effects of cannabis use". Drug and Alcohol Review. 29 (3): 318–30. doi:10.1111/j.1465-3362.2009.00149.x. PMID 20565525.
- Borges G, Bagge CL, Orozco R (May 2016). "A literature review and meta-analyses of cannabis use and suicidality". Journal of Affective Disorders. 195: 63–74. doi:10.1016/j.jad.2016.02.007. PMID 26872332.
- Lev-Ran S, Roerecke M, Le Foll B, George TP, McKenzie K, Rehm J (March 2014). "The association between cannabis use and depression: a systematic review and meta-analysis of longitudinal studies". Psychological Medicine. 44 (4): 797–810. doi:10.1017/S0033291713001438. PMID 23795762.
- Kedzior KK, Laeber LT (May 2014). "A positive association between anxiety disorders and cannabis use or cannabis use disorders in the general population—a meta-analysis of 31 studies". BMC Psychiatry. 14: 136. doi:10.1186/1471-244X-14-136. PMC 4032500. PMID 24884989.
- Gobbi, Gabriella; Atkin, Tobias; Zytynski, Tomasz; Wang, Shouao; Askari, Sorayya; Boruff, Jill; Ware, Mark; Marmorstein, Naomi; Cipriani, Andrea; Dendukuri, Nandini; Mayo, Nancy (13 February 2019). "Cannabis Use in Adolescence and Risk of Depression, Anxiety, and Suicidality in Young Adulthood". JAMA Psychiatry. 76 (4): 426–434. doi:10.1001/jamapsychiatry.2018.4500. PMC 6450286. PMID 30758486.
- Hall W, Degenhardt L (October 2009). "Adverse health effects of non-medical cannabis use". Lancet. 374 (9698): 1383–91. doi:10.1016/s0140-6736(09)61037-0. PMID 19837255. S2CID 31616272.
- Subbaraman MS (2014). "Can cannabis be considered a substitute medication for alcohol?". Alcohol and Alcoholism. 49 (3): 292–8. doi:10.1093/alcalc/agt182. PMC 3992908. PMID 24402247.
- Hall W, Pacula RL (2003). Cannabis Use and Dependence: Public Health and Public Policy. Cambridge University Press. p. 15. ISBN 978-0-521-80024-2.
- Hollister LE, et al. (March 1986). "Health aspects of cannabis". Pharma Review. 38 (38): 1–20. PMID 3520605. Archived from the original on 15 April 2013. Retrieved 17 February 2011.
- Iovanna J, Ismailov U (2009). Pancreatology: From Bench to Bedside. Springer. p. 40. ISBN 978-3-642-00152-9.
- Wilson RI, Nicoll RA (April 2002). "Endocannabinoid signaling in the brain" (PDF). Science. 296 (5568): 678–82. Bibcode:2002Sci...296..678W. doi:10.1126/science.1063545. PMID 11976437. S2CID 21573145. Archived from the original (PDF) on 26 February 2020.
- Oleson EB, Cheer JF (August 2012). "A brain on cannabinoids: the role of dopamine release in reward seeking". Cold Spring Harbor Perspectives in Medicine. 2 (8): a012229. doi:10.1101/cshperspect.a012229. PMC 3405830. PMID 22908200.
- Kathmann M, Flau K, Redmer A, Tränkle C, Schlicker E (February 2006). "Cannabidiol is an allosteric modulator at mu- and delta-opioid receptors". Naunyn-Schmiedeberg's Archives of Pharmacology. 372 (5): 354–61. doi:10.1007/s00210-006-0033-x. PMID 16489449. S2CID 4877869.
- Hejazi N, Zhou C, Oz M, Sun H, Ye JH, Zhang L (March 2006). "Delta9-tetrahydrocannabinol and endogenous cannabinoid anandamide directly potentiate the function of glycine receptors" (PDF). Molecular Pharmacology. 69 (3): 991–7. doi:10.1124/mol.105.019174. PMID 16332990. S2CID 21801428. Archived from the original (PDF) on 7 March 2019.
- Xiong W, Cheng K, Cui T, Godlewski G, Rice KC, Xu Y, Zhang L (May 2011). "Cannabinoid potentiation of glycine receptors contributes to cannabis-induced analgesia". Nature Chemical Biology. 7 (5): 296–303. doi:10.1038/nchembio.552. PMC 3388539. PMID 21460829.
- Baselt RC (2008). Disposition of Toxic Drugs and Chemicals in Man. Biomedical Publications. pp. 1513–1518. ISBN 978-0-9626523-7-0.
- Shaw LM, Kwong TC (2001). The Clinical Toxicology Laboratory: Contemporary Practice of Poisoning Evaluation. Amer. Assoc. for Clinical Chemistry. p. 51. ISBN 978-1-890883-53-9.
- "The Non-Specificity of the Duquenois-Levine Field Test for Marijuana". ResearchGate.
- Venkatratnam A, Lents NH (July 2011). "Zinc reduces the detection of cocaine, methamphetamine, and THC by ELISA urine testing". Journal of Analytical Toxicology. 35 (6): 333–40. doi:10.1093/anatox/35.6.333. PMID 21740689.
- Lin CN, Strathmann FG (10 July 2013). "Elevated urine zinc concentration reduces the detection of methamphetamine, cocaine, THC and opiates in urine by EMIT". Journal of Analytical Toxicology. 37 (9): 665–9. doi:10.1093/jat/bkt056. PMID 23843421.
- Joy JE, Watson SJ, Benson JA (1999). Marijuana and Medicine: Assessing The Science Base. Washington, D.C.: National Academy of Sciences Press. doi:10.17226/6376. ISBN 978-0-585-05800-9. PMID 25101425.
- Elliott S. "The Ultimate Guide on Indicas vs. Sativas". Herb. Retrieved 22 June 2018.
- Piomelli D, Russo EB (2016). "The Cannabis sativa Versus Cannabis indica Debate: An Interview with Ethan Russo, MD". Cannabis and Cannabinoid Research. 1 (1): 44–46. doi:10.1089/can.2015.29003.ebr. PMC 5576603. PMID 28861479.
- "Why Does Cannabis Potency Matter?". United Nations Office on Drugs and Crime. 29 June 2009.
- Cascini F, Aiello C, Di Tanna G (March 2012). "Increasing delta-9-tetrahydrocannabinol (Δ-9-THC) content in herbal cannabis over time: systematic review and meta-analysis" (PDF). Current Drug Abuse Reviews. 5 (1): 32–40. doi:10.2174/1874473711205010032. PMID 22150622. S2CID 24350419. Archived from the original (PDF) on 8 March 2019.
- Smith D (17 January 2014). "Cannabis and memory loss: dude, where's my CBD?". the Guardian.
- "Cannabis Potency". National Cannabis Prevention and Information Centre. Archived from the original on 6 December 2011. Retrieved 13 December 2011.
- "BBC: Cannabis laws to be strengthened. May 2008 20:55 UK". BBC News. 7 May 2008. Retrieved 20 September 2010.
- Di Forti M, Morgan C, Dazzan P, Pariante C, Mondelli V, Marques TR, Handley R, Luzi S, et al. (December 2009). "High-potency cannabis and the risk of psychosis". The British Journal of Psychiatry. 195 (6): 488–91. doi:10.1192/bjp.bp.109.064220. PMC 2801827. PMID 19949195.
- Hope, Christopher (6 February 2008). "Use of extra strong 'skunk' cannabis soars". The Daily Telegraph. London.
- Doweiko H (2011). Concepts of Chemical Dependency. Cengage Learning. p. 124. ISBN 978-1-133-17081-5.
- "Fake Hanf: Ein Drogentrend schwappt in die Schweiz – was du darüber wissen musst". watson.ch (in German).
- "Fake Hanf: Tödliches Marihuana hat bereits 61 Menschen getötet". watson.ch (in German).
- "Fake Hanf mit synthetischen Cannabinoiden besprüht - drugcom". www.drugcom.de.
- "Tödlicher Fake Hanf - Chemisch behandelte Hanfblüten – niemand kann sie erkennen". Schweizer Radio und Fernsehen (SRF) (in German). 14 August 2020.
- Potter G, Bouchard M, Decorte T (2013). World Wide Weed: Global Trends in Cannabis Cultivation and its Control (revised ed.). Ashgate Publishing, Ltd. p. 17. ISBN 978-1-4094-9438-6.
- Hall W, Pacula RL (2003). Cannabis Use and Dependence: Public Health and Public Policy. Cambridge University Press. p. 13. ISBN 978-0-521-80024-2.
- United Nations Office on Drugs and Crime (2009). Recommended Methods for the Identification and Analysis of Cannabis and Cannabis Products. United Nations Publications. p. 15. ISBN 978-92-1-148242-3.
- Houck MM (2015). Forensic Chemistry. Elsevier Science. p. 131. ISBN 978-0-12-800624-5.
- Adler PA, Adler P, O'Brien PK (28 February 2012). Drugs and the American Dream: An Anthology. John Wiley & Sons. pp. 330–. ISBN 978-0-470-67027-9.
- Mosher CJ, Akins SM (20 August 2013). Drugs and Drug Policy: The Control of Consciousness Alteration. SAGE Publications. p. 17. ISBN 978-1-4833-2188-2.
- "Hemp Facts". Naihc.org. Archived from the original on 27 November 2012. Retrieved 9 January 2013.
- Earleywine, Mitch (2002). Understanding Marijuana: A New Look at the Scientific Evidence. Oxford University Press. p. 3. ISBN 978-0-19-988143-7.
- Rosenthal E (2002). Ask Ed : Marijuana Gold: Trash to Stash. QUICK AMER Publishing Company. p. 116. ISBN 978-0-932551-52-8.
- "Kief". Cannabisculture.com. 9 March 2005. Archived from the original on 5 June 2009. Retrieved 2 January 2010.
- Bukszpan D (2012). Is That a Word?: From AA to ZZZ, the Weird and Wonderful Language of SCRABBLE. Chronicle Books. p. 94. ISBN 978-1-4521-0824-7.
- "Hashish". dictionary.reference.com.
- Castle/Murray/D'Souza (2004). Marijuana and Madness. Cambridge University Press. p. 35. ISBN 978-1-139-50267-2.
- Goldberg R (2012). Drugs Across the Spectrum (7th ed.). Cengage Learning. p. 255. ISBN 978-1-133-59416-1.
- Alchimia Blog, Rosin Hash
- Iversen LL (2000). The Science of Marijuana. Oxford University Press. p. 17. ISBN 978-0-19-515110-7.
- Cohen JA, Rudick RA (2011). Multiple Sclerosis Therapeutics. Cambridge University Press. p. 670. ISBN 978-1-139-50237-5.
- King LA (2009). Forensic Chemistry of Substance Misuse: A Guide to Drug Control. Royal Society of Chemistry. p. 78. ISBN 978-0-85404-178-7.
- "Dabs—marijuana's explosive secret". Cnbc.com. 24 February 2014. Retrieved 28 February 2014.
- World Drug Report. United Nations Publications. 2009. p. 98. ISBN 9789211482409.
- Alison Hallett for Wired. 20 February 2013 Hash Oil is Blowing Up Across the U.S. –Literally
- Kintz P (2014). Toxicological Aspects of Drug-Facilitated Crimes. Elsevier Science. p. 141. ISBN 978-0-12-416969-2.
- McDonough E (2012). The Official High Times Cannabis Cookbook: More Than 50 Irresistible Recipes That Will Get You High. Chronicle Books. p. 17. ISBN 978-1-4521-0133-0.
- Backes M (2014). Cannabis Pharmacy: The Practical Guide to Medical Marijuana. Hachette Books. p. 46. ISBN 978-1-60376-334-9.
- Ainge Roy, Eleanor (11 December 2018). "New Zealand passes laws to make medical marijuana widely available". The Guardian. Retrieved 20 January 2019.
- Schultes, Richard Evans (1976). Hallucinogenic Plants. Illustrated by Elmer W. Smith. New York: Golden Press. p. 31. ISBN 978-0-307-24362-1.
- "Marijuana and the Cannabinoids", ElSohly (p. 8).
- Stafford PG, Bigwood J (1992). Psychedelics Encyclopedia. Ronin Publishing. p. 157. ISBN 978-0-914171-51-5.
- Barber EJ (1992). Prehistoric Textiles: The Development of Cloth in the Neolithic and Bronze Ages with Special Reference to the Aegean. Princeton University Press. p. 17.
- Anthony, David W. (2007). The Horse, the Wheel, and Language: How Bronze-Age Riders from the Eurasian Steppes Shaped the Modern World. Princeton University Press. p. 362. ISBN 978-0-691-05887-0.
- Ellens, J. Harold (2014). Seeking the Sacred with Psychoactive Substances: Chemical Paths to Spirituality and to God. ABC-CLIO. pp. 24, 31. ISBN 978-1440830884.
- Rudgley R (1998). "Soma". The Encyclopedia of Psychoactive Substances. Little, Brown and Company. ISBN 978-0-349-11127-8.
- Franck M (1997). Marijuana Grower's Guide. Red Eye Press. p. 3. ISBN 978-0-929349-03-9.
- Rubin VD (1976). Cannabis and Culture. Campus Verlag. p. 305. ISBN 978-3-593-37442-0.
- Cunliffe BW (2001). The Oxford Illustrated History of Prehistoric Europe. Oxford University Press. p. 405. ISBN 978-0-19-285441-4.
- Schultes, Richard Evans (1976). Hallucinogenic Plants. Illustrated by Elmer W. Smith. New York: Golden Press. p. 34. ISBN 978-0-307-24362-1.
- Staelens, Stefanie (10 March 2015). "The Bhang Lassi Is How Hindus Drink Themselves High for Shiva". Vice.com. Retrieved 10 August 2017.
- Ren M, Tang Z, Wu X, Spengler R, Jiang H, Yang Y, Boivin N (June 2019). "The origins of cannabis smoking: Chemical residue evidence from the first millennium BCE in the Pamirs". Science Advances. 5 (6): eaaw1391. Bibcode:2019SciA....5.1391R. doi:10.1126/sciadv.aaw1391. PMC 6561734. PMID 31206023.
- Walton RP (1938). Marijuana, America's New Drug Problem. JB Lippincott. p. 6.
- Taymiyya I (2001). Le haschich et l'extase (in French). Beyrouth: Albouraq. ISBN 978-2-84161-174-4.
- Rubin V (1 January 1975). Cannabis and Culture. Walter de Gruyter. pp. 77–. ISBN 978-3-11-081206-0.
Cannabis Smoking in 13th-14th Century Ethiopia: Chemical Evidence
- Iversen LL (7 December 2007). The Science of Marijuana. Oxford University Press. pp. 110–. ISBN 978-0-19-988693-7.
- A Collection of the Laws of Mauritius and Its Dependencies. By the authority of the Government. 1867. pp. 541–.
- Bunyapraphatsōn N (1999). Medicinal and poisonous plants. Backhuys Publishers. p. 169. ISBN 978-90-5782-042-7.
- "Statement of Dr. William C. Woodward". Drug library. Retrieved 20 September 2010.
- The Opium and Narcotic Drug Act, 1923, S.C. 1923, c. 22
- Willoughby WW (1925). "Opium as an international problem". Baltimore: The Johns Hopkins Press. Retrieved 20 September 2010.
- Opium as an international problem: the Geneva conferences – Westel Woodbury Willoughby at Google Books
- Pub.L. 75–238, 50 Stat. 551, enacted August 2, 1937
- Booth M (1 June 2005). Cannabis: A History. Picador. pp. 338–. ISBN 978-0-312-42494-7.
- Michael Tonry (22 September 2015). Crime and Justice. A Review of Research. 44. University of Chicago Press. pp. 261–. ISBN 978-0-226-34102-6.
- Use drop-down menu on site to view Netherlands entry.), Eldd.emcdda.europa.eu, retrieved 17 February 2011
- Drugs Policy in the Netherlands, Ukcia.org, archived from the original on 2 August 2017, retrieved 17 February 2011
- "Amsterdam Will Ban Tourists from Pot Coffee Shops". Atlantic Wire. 27 May 2011. Retrieved 23 June 2011.
- Dockterman E (29 June 2012). "Marijuana Now the Most Popular Drug in the World". Time NewsFeed. Time Inc. Retrieved 16 March 2013.
- "Factsheet". World Drug Report 2017. United Nation Office on Drugs and Crime (UNODC).
- Jikomes, Nick (24 March 2017). "A list of major cannabinoids in cannabis and their effects". Leafly. Retrieved 25 October 2020.
- Rahn, Bailey (12 February 2014). "What are cannabis terpenes and what do they do?". Leafly. Retrieved 25 October 2020.
- Levinson D (2002). Encyclopedia of Crime and Punishment. SAGE Publications. p. 572. ISBN 978-0-7619-2258-2.
- "Many Dutch coffee shops close as liberal policies change, Exaptica". Expatica.com. 27 November 2007. Archived from the original on 29 April 2011. Retrieved 20 September 2010.
- "43 Amsterdam coffee shops to close door", Radio Netherlands, Friday 21 November 2008 Archived 2 December 2008 at the Wayback Machine
- O'Sullivan F (3 March 2014). "Why the Mayor of Copenhagen Wants to Get Into the Marijuana Business". Retrieved 23 January 2018.
- Johnston I (5 January 2014). "As cannabis is widely legalised, China cashes in on an unprecedented boom". Independent. Retrieved 23 January 2018.
- Liljas P (3 June 2017). "Could Thailand, which gave world the bong, legalise cannabis for medicinal use? After failed war on drugs, attitudes have softened". Post Magazine. Retrieved 23 January 2018.
- "Marijuana goes legal in Washington state amid mixed messages". Reuters. 7 December 2012. Retrieved 14 December 2012.
- Duke A (8 November 2012). "2 states legalize pot, but don't 'break out the Cheetos' yet". CNN.com. Retrieved 2 January 2013.
- "Marijuana clubs ring in new year in Colorado as legalized pot smoking begins". Abcnews.go.com. 1 January 2013. Retrieved 2 January 2013.
- Mintz H (6 May 2013). "Medical pot: California Supreme Court allows cities to ban weed dispensaries". Marin Independent Journal. Archived from the original on 2 November 2013.
- Baker V (11 December 2013). "Marijuana laws around the world: what you need to know". the Guardian.
- Reuters (19 July 2017). "Uruguay pharmacies start selling cannabis straight to consumers" – via www.theguardian.com.
- "Marijuana to be legal in Canada starting October 17, Trudeau confirms". 20 June 2018.
- Sapra, Bani. "Canada becomes second nation in the world to legalize marijuana".
- "Uttarakhand To Become First Indian State To Legalise Cannabis Cultivation". Indiatimes. 27 November 2015. Retrieved 12 March 2017.
- "South Asia Regional Profile Report" (PDF). UNODC.
- Alchimia Blog, Medical marijuana news, December 2015
- Butler, Patrick (17 October 2018). "Cannabis is legal in Canada — here's what you need to know". CBC. Retrieved 1 November 2018.
- Sapra, Bani (20 June 2018). "Canada becomes second nation in the world to legalize marijuana". CNN. Retrieved 1 November 2018.
- "This Application Seems Rigorous. Are All These Hoops Necessary?". LicensedProducersCanada.com. Retrieved 1 November 2018.
- "Will Craft Cannabis Growers in Canada Succeed Like Craft Brewers?". LicensedProducersCanada.com. Retrieved 1 November 2018.
- Parliament of the Czech Republic (1998), Explanatory Report to Act No. 112/1998 Coll., which amends the Act No. 140/1961 Coll., the Criminal Code, and the Act No. 200/1990 Coll., on misdemeanors (in Czech), Prague "Podle čl. 36 Jednotné úmluvy o omamných látkách ze dne 31. března 1961 (č. 47/1965 Sb.) se signatáři zavazují k trestnímu postihu tam uvedených forem nakládání s drogami včetně jejich držby. Návrh upouští od dosavadní beztrestnosti držby omamných a psychotropních látek a jedů pro svoji potřebu. Dosavadní beztrestnost totiž eliminuje v řadě případů možnost postihu dealerů a distributorů drog."
- Castaneda JG. "The summit of muted intentions". aljazeera.com.
- "Congreso aprobó, en último debate, uso medicinal de la marihuana". 25 May 2016.
- "Dosis máximas de droga para consumo ya están vigentes" Archived 2013-06-24 at the Wayback Machine at El Comercio.com.
- "Ecuador: Aprueban tenencia de drogas para consumo" Archived 2013-06-25 at the Wayback Machine at El Nuevo Herald
- "Ecuador could regulate the drug industry". Archived from the original on 24 June 2013.
- "Drug policy profiles — Portugal" (PDF). 1 June 2011. Retrieved 5 February 2017.
- Lindeque, Mia. "Dagga users celebrate following ConCourt ruling on private use". Retrieved 3 November 2018.
- Williams, Sean (28 April 2019). "Mexico Aims to Legalize Recreational Marijuana Before October –". The Motley Fool. Retrieved 29 April 2019.
- Ley de Narcomenudeo Archived 2010-11-30 at the Wayback Machine, El Pensador (in Spanish), 17 October 2009
- Mexico: The Law Against Small-Scale Drug Dealing. A Doubtful Venture, Jorge Hernández Tinajero & Carlos Zamudio Angles, Series on Legislative Reform of Drug Policies Nr. 3, November 2009
- "Annual prevalence of use of drugs, by region and globally, 2016". World Drug Report 2018. United Nations Office on Drugs and Crime. 2018. Retrieved 7 July 2018.
- Caulkins JP, Hawken A, Kilmer B, Kleiman MA (27 September 2012). Marijuana Legalization: What Everyone Needs to Know. Oxford University Press. p. 16. ISBN 978-0199913732.
- Joshua CD (2015). "The business of getting high: head shops, countercultural capitalism, and the marijuana legalization movement". The Sixties. 8: 27–49. doi:10.1080/17541328.2015.1058480. hdl:11603/7422. S2CID 142795620.
- "6 facts about marijuana". 22 November 2018. Retrieved 24 September 2020.
- "Daily marijuana use among college students highest since 1980". The University Record.
- McCarthy, Justin (22 July 2015). "More Than Four in 10 Americans Say They Have Tried Marijuana". Gallup.
- "World Drug Report 2006". United Nations Office on Drugs and Crime. Ch. 2.3.
- Turco, Bucky (25 September 2017). "Why is Weed Getting More Potent". Gizmodo.
- Forbes D (19 November 2002). "The Myth of Potent Pot". Slate.com.
- "Cannabis: Wholesale, street prices and purity levels" (PDF). UNODC.org. 2005. Retrieved 9 January 2013.
- "Report on U.S. Domestic Marijuana Production". NORML. Archived from the original on 26 December 2009. Retrieved 2 January 2010.
- "Marijuana Called Top U.S. Cash Crop". 2008 ABCNews Internet Ventures. 20 December 2006.
- United Nations Office on Drugs and Crime (2008). World drug report (PDF). United Nations Publications. p. 268. ISBN 978-92-1-148229-4.
- Sharma, Rakesh (25 June 2019). "How Federal Legalization Could Transform The US Cannabis Market". Investopedia. Retrieved 24 July 2019.
- Hughes, Trevor (23 May 2019). "As marijuana prices drop, growers push 'organic' cannabis – with a higher price tag". USA TODAY. Retrieved 24 July 2019.
- European Monitoring Centre for Drugs and Drug Addiction (2008). Annual report: the state of the drugs problem in Europe (PDF). Luxembourg: Office for Official Publications of the European Communities. p. 38. ISBN 978-92-9168-324-6.
- "RAND study casts doubt on claims that marijuana acts as a "gateway" to the use of cocaine and heroin". RAND Corporation. 2 December 2002. Archived from the original on 4 November 2006.
- "Public Views of Marijuana – Legalization, Decriminalization, Concerns | Pew Research Center for the People and the Press". 2 April 2014.
- Mosher CJ, Akins S (2007). Drugs and Drug Policy: The Control of Consciousness Alteration. SAGE Publications. p. 18. ISBN 978-0-7619-3007-5.
- Saitz R (18 February 2003). "Is marijuana a gateway drug?". Journal Watch. 2003 (218): 1. Archived from the original on 10 July 2003.
- Degenhardt L, Coffey C, Carlin JB, Moran P, Patton GC (August 2007). "Who are the new amphetamine users? A 10-year prospective study of young Australians". Addiction. 102 (8): 1269–79. doi:10.1111/j.1360-0443.2007.01906.x. PMID 17624977.
- "3 The Experience of Drug Users". 2009/10 Scottish Crime and Justice Survey: Drug Use. The Scottish Government. 21 January 2011. Retrieved 5 November 2013.
- Morral AR, McCaffrey DF, Paddock SM (December 2002). "Reassessing the marijuana gateway effect" (PDF). Addiction. 97 (12): 1493–504. doi:10.1046/j.1360-0443.2002.00280.x. PMID 12472629. S2CID 2833456. Archived from the original (PDF) on 22 June 2020.
- "Marijuana Policy Project – FAQ". Archived from the original on 22 June 2008.
- Torabi MR, Bailey WJ, Majd-Jabbari M (September 1993). "Cigarette smoking as a predictor of alcohol and other drug use by children and adolescents: evidence of the "gateway drug effect"". The Journal of School Health. 63 (7): 302–6. doi:10.1111/j.1746-1561.1993.tb06150.x. PMID 8246462.
- Vanyukov MM, Tarter RE, Kirillova GP, Kirisci L, Reynolds MD, Kreek MJ, Conway KP, Maher BS, Iacono WG, Bierut L, Neale MC, Clark DB, Ridenour TA (June 2012). "Common liability to addiction and "gateway hypothesis": theoretical, empirical and evolutionary perspective". Drug and Alcohol Dependence (Review). 123 Suppl 1: S3–17. doi:10.1016/j.drugalcdep.2011.12.018. PMC 3600369. PMID 22261179.
- "Marijuana Research Report:Is marijuana a gateway drug?". National Institute on Drug Abuse. July 2020. Retrieved 7 November 2020.
- "Marijuana Research: Current restrictions on marijuana research are absurd". Scientific American. 22 November 2004. Archived from the original on 7 November 2010. Retrieved 15 January 2013.
- Ponto LL (May 2006). "Challenges of marijuana research". Brain. 129 (Pt 5): 1081–3. doi:10.1093/brain/awl092. PMID 16627464.
- Jha A (31 May 2012). "Ecstasy and cannabis should be freely available for study, says David Nutt". The Guardian. Retrieved 15 January 2013.
- "Medical Marijuana Policy in the United States". Stanford.edu. 15 May 2012. Retrieved 15 January 2013.
- Conaboy C (19 October 2012). "Research into marijuana's medical benefits limited; scientists cite challenge of studying an illegal drug". Boston Globe. Archived from the original on 21 October 2012. Retrieved 15 January 2013.
- "FDA and Cannabis: Research and Drug Approval Process". US Food and Drug Administration. 14 January 2020. Retrieved 21 January 2020.
- Peters EN, Budney AJ, Carroll KM (August 2012). "Clinical correlates of co-occurring cannabis and tobacco use: a systematic review". Addiction. 107 (8): 1404–17. doi:10.1111/j.1360-0443.2012.03843.x. PMC 3377777. PMID 22340422.
- "Does smoking cannabis cause cancer?". Cancer Research UK (CRUK). 30 August 2017.
- Iseger TA, Bossong MG (March 2015). "A systematic review of the antipsychotic properties of cannabidiol in humans". Schizophrenia Research. 162 (1–3): 153–61. doi:10.1016/j.schres.2015.01.033. PMID 25667194. S2CID 3745655.
- Black, Nicola; Stockings, Emily; Campbell, Gabrielle; Tran, Lucy T.; Zagic, Dino; Hall, Wayne D.; Farrell, Michael; Degenhardt, Louisa (December 2019). "Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis". The Lancet. Psychiatry. 6 (12): 995–1010. doi:10.1016/S2215-0366(19)30401-8. ISSN 2215-0374. PMC 6949116. PMID 31672337.
- VanDolah, Harrison J.; Bauer, Brent A.; Mauck, Karen F. (September 2019). "Clinicians' Guide to Cannabidiol and Hemp Oils". Mayo Clinic Proceedings. 94 (9): 1840–1851. doi:10.1016/j.mayocp.2019.01.003. ISSN 1942-5546. PMID 31447137.
- Greger, Jessica; Bates, Vernice; Mechtler, Laszlo; Gengo, Fran (2020). "A review of cannabis and interactions with anticoagulant and antiplatelet agents". The Journal of Clinical Pharmacology. 60 (4): 432–438. doi:10.1002/jcph.1557. ISSN 0091-2700. PMID 31724188. S2CID 208019237.
- Ross, Selena (6 June 2018). "All eyes on Canada as first G7 nation prepares to make marijuana legal". The Guardian. Retrieved 10 July 2018.
- Sapra, Bani (20 June 2018). "Canada becomes second nation in the world to legalize marijuana". CNN.
- Smith, Tasha (5 June 2018). ""New Amsterdam" No More? Spain's Cannabis Clubs Fight to Stay Open". Merry Jane. Retrieved 23 August 2018.
- Haines, Gavin (21 February 2017). "Everything you need to know about marijuana smoking in the Netherlands". The Telegraph. Retrieved 22 July 2018.
|Look up marijuana in Wiktionary, the free dictionary.|